Higher efficacy of anti-IL-6/IL-21 combination therapy compared to monotherapy in the induction phase of Th17-driven experimental arthritis

The role of the Th17 cytokines IL-17 and IL-22 in Rheumatoid Arthritis pathogenesis and developments in cytokine immunotherapy

(2015) Debbie M. Roeleveld et al.   CYTOKINE

A Study to Evaluate the Safety, Tolerability, and Efficacy of Brodalumab in Subjects with Rheumatoid Arthritis and an Inadequate Response to Methotrexate

(2015) K. Pavelka et al.   JOURNAL OF RHEUMATOLOGY

Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial

(2015) Iain B McInnes et al.   LANCET

Secukinumab, an Interleukin-17A Inhibitor, in Ankylosing Spondylitis

(2015) Dominique Baeten et al.   NEW ENGLAND JOURNAL OF MEDICINE

Secukinumab Inhibition of Interleukin-17A in Patients with Psoriatic Arthritis

(2015) Philip J. Mease et al.   NEW ENGLAND JOURNAL OF MEDICINE

Association ofHLA-DRB1alleles with clinical responses to the anti-interleukin-17A monoclonal antibody secukinumab in active rheumatoid arthritis

(2015) Gerd R. Burmester et al.   RHEUMATOLOGY

Novel therapeutic targets in rheumatoid arthritis

(2015) Marije I. Koenders et al.   TRENDS IN PHARMACOLOGICAL SCIENCES

Tocilizumab for treating rheumatoid arthritis: an evaluation of pharmacokinetics/pharmacodynamics and clinical efficacy

(2014) Soken-Nakazawa J Song et al.   Expert Opinion on Drug Metabolism & Toxicology

Cutting Edge: IL-21 Is Not Essential for Th17 Differentiation or Experimental Autoimmune Encephalomyelitis

(2014) J. M. Coquet et al.   JOURNAL OF IMMUNOLOGY

One-year Efficacy and Safety Results of Secukinumab in Patients With Rheumatoid Arthritis: Phase II, Dose-finding, Double-blind, Randomized, Placebo-controlled Study

(2014) M. C. Genovese et al.   JOURNAL OF RHEUMATOLOGY

Study of active controlled tocilizumab monotherapy for rheumatoid arthritis patients with an inadequate response to methotrexate (SATORI): significant reduction in disease activity and serum vascular endothelial growth factor by IL-6 receptor inhibition therapy

(2014) Norihiro Nishimoto et al.   Modern Rheumatology

A Phase II Randomized Study of Subcutaneous Ixekizumab, an Anti-Interleukin-17 Monoclonal Antibody, in Rheumatoid Arthritis Patients Who Were Naive to Biologic Agents or Had an Inadequate Response to Tumor Necrosis Factor Inhibitors

(2014) Mark C. Genovese et al.   Arthritis & Rheumatology

IL-22+CD4+T cells in patients with rheumatoid arthritis

(2013) Ling Zhao et al.   International Journal of Rheumatic Diseases

The Cellular Source and Target of IL-21 in K/BxN Autoimmune Arthritis

(2013) K. E. Block et al.   JOURNAL OF IMMUNOLOGY

A phase Ib multiple ascending dose study evaluating safety, pharmacokinetics, and early clinical response of brodalumab, a human anti-IL-17R antibody, in methotrexate-resistant rheumatoid arthritis

(2013) David A Martin et al.   ARTHRITIS RESEARCH & THERAPY

Interleukin-21 Receptor Deficiency Increases the Initial Toll-like Receptor 2 Response but Protects Against Joint Pathology by Reducing Th1 and Th17 Cells During Streptococcal Cell Wall Arthritis

(2013) Renoud J. Marijnissen et al.   Arthritis & Rheumatology

Incomplete response of inflammatory arthritis to TNFα blockade is associated with the Th17 pathway

(2012) Saba Alzabin et al.   ANNALS OF THE RHEUMATIC DISEASES

Efficacy and safety of secukinumab in patients with rheumatoid arthritis: a phase II, dose-finding, double-blind, randomised, placebo controlled study

(2012) Mark C Genovese et al.   ANNALS OF THE RHEUMATIC DISEASES

Brief Report: Inhibition of interleukin-6 function corrects Th17/Treg cell imbalance in patients with rheumatoid arthritis

(2012) Maxime Samson et al.   ARTHRITIS AND RHEUMATISM

Brodalumab, an Anti–Interleukin-17–Receptor Antibody for Psoriasis

(2012) Kim A. Papp et al.   NEW ENGLAND JOURNAL OF MEDICINE

Interleukin 22 serum levels are associated with radiographic progression in rheumatoid arthritis

(2011) J. Leipe et al.   ANNALS OF THE RHEUMATIC DISEASES

Tumor necrosis factor-interleukin-17 interplay induces S100A8, interleukin-1β, and matrix metalloproteinases, and drives irreversible cartilage destruction in murine arthritis: Rationale for combination treatment during arthritis

(2011) Marije I. Koenders et al.   ARTHRITIS AND RHEUMATISM

Interleukin-21 promotes osteoclastogenesis in humans with rheumatoid arthritis and in mice with collagen-induced arthritis

(2011) Seung-Ki Kwok et al.   ARTHRITIS AND RHEUMATISM

Interleukin-22 promotes osteoclastogenesis in rheumatoid arthritis through induction of RANKL in human synovial fibroblasts

(2011) Kyoung-Woon Kim et al.   ARTHRITIS AND RHEUMATISM

Increasing levels of circulating Th17 cells and interleukin-17 in rheumatoid arthritis patients with an inadequate response to anti-TNF-α therapy

(2011) Der-Yuan Chen et al.   ARTHRITIS RESEARCH & THERAPY

LY2439821, a humanized anti-interleukin-17 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: A phase I randomized, double-blind, placebo-controlled, proof-of-concept study

(2010) M. C. Genovese et al.   ARTHRITIS AND RHEUMATISM

Increased IL-17 production by peripheral T helper cells after tumour necrosis factor blockade in rheumatoid arthritis is accompanied by inhibition of migration-associated chemokine receptor expression

(2010) N. E. Aerts et al.   RHEUMATOLOGY

IL-6 blockade preferentially inhibits Th17 differentiation in collagen-induced arthritis

(2010) Hiroto Yoshida et al.   RHEUMATOLOGY INTERNATIONAL

Effects of AIN457, a Fully Human Antibody to Interleukin-17A, on Psoriasis, Rheumatoid Arthritis, and Uveitis

(2010) W. Hueber et al.   Science Translational Medicine

Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study

(2009) G. Jones et al.   ANNALS OF THE RHEUMATIC DISEASES

Human rheumatoid arthritis tissue production of IL-17A drives matrix and cartilage degradation: synergy with tumour necrosis factor-α, Oncostatin M and response to biologic therapies

(2009) Ellen M Moran et al.   ARTHRITIS RESEARCH & THERAPY

IL‐21 and IL‐21R are not required for development of Th17 cells and autoimmunityin vivo

(2008) Ivo Sonderegger et al.   EUROPEAN JOURNAL OF IMMUNOLOGY

IL-21 and TGF-β are required for differentiation of human TH17 cells

(2008) Li Yang et al.   NATURE